| Name | Nafamostat mesylate |
| Description | Nafamostat mesylate (FUT-175), a synthetic serine protease inhibitor, has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. |
| In vitro | Nafamostat Mesylate inhibits both the activation of NF-κB and apoptosis induced by gemcitabine and restrains the growth of pancreatic tumors. At a dosage of 10 mg/kg, it exhibits an inhibitory effect on wounds induced by trypsin. Furthermore, at the same dosage, Nafamostat Mesylate suppresses tryptase activity in mouse skin. |
| In vivo | Nafamostat mesilate significantly inhibits the release of platelet β-thromboglobulin (βTG) and the release of elastase from neutrophils. It also prevents the formation of complexes between the C1 inhibitor and both prekallikrein and FXIIa. Furthermore, Nafamostat mesilate inhibits the extrinsic pathway activity mediated by the TF-F.VIIa complex, leading to the production of F.Xa, with an IC50 value of 0.1 μM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 121 mg/mL (224.25 mM), Sonication is recommended.
H2O : 54 mg/mL (100.08 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (7.41 mM), Sonication is recommended.
|
| Keywords | threoninkinase | Threonine proteases | threonin kinase | SerineProtease | Serinekinase | Serine proteases | Serine Protease | Serine kinase | Serine endopeptidases | Ser/Thr Protease | SARS-CoV | SARSCoV | SARS coronavirus | Nafamostat mesylate | Nafamostat Mesylate | Nafamostat | Inhibitor | inhibit | FUT175 | FUT 175 | Apoptosis |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Hydroxychloroquine | Metronidazole | Fumaric acid | Citric Acid Triammonium | Imidazole | 1,8-Cineole | Tributyrin | (E)-3-(p-Tolyl)acrylaldehyde | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
United States
